Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT03131219 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03131219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03131219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2017
Completion date
December 20, 2022
Enrollment
34 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

atypical hemolytic uremic syndrome (ahus)